Haemodynamic Effects of New β-Blockers with Vasodilatory Properties in Essential Hypertension

Tsukiyama, Hisaichiro; Otsuka, Keiko; Horii, Masako

doi:10.2165/00003495-198800366-00009

Cited by 7 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to these unwanted side effects of the 'classical' beta-blocking agents, a new generation of beta-blockers has been developed in recent years, suggested to be devoid of alpha-receptor mediated vasoconstriction [3,4]. One example of these third-generation beta-blockers is celiprolol.…”

Section: Introductionmentioning

confidence: 99%

Cardiovascular Effects of Beta-Blockers with and without Intrinsic Sympathomimetic Activity

Heusser

Schobel²,

Adamidis³

et al. 2002

Kidney Blood Press Res

View full text Add to dashboard Cite

Background: Celiprolol, a newer beta-blocking agent, has been reported to have vasodilatory capacity which may be due to partial beta-2-receptor agonistic activity or to alpha-receptor antagonistic or central sympathoinhibitory effects. Methods: To more critically assess the physiologic effects of celiprolol, we measured sympathetic nerve activity to muscle (MSNA), forearm blood flow (FBF), blood pressure (BP), central venous pressure, and heart rate (HR) in 10 normal volunteers at rest, during unloading of cardiopulmonary baroreceptors with lower body negative pressure (LBNP), and during a cold pressor test (CPT). Responses were compared with those seen with metoprolol and with placebo, i.e. each subject was studied three times. Results: Celiprolol did not alter resting levels of hemodynamics, FBF, and MSNA nor did it alter responses to LBNP or the CPT. In contrast, metoprolol produced significant decreases of FBF and HR, and increases of forearm vascular resistance and BP, but had also no effect on responses to the applied stress tests. Conclusions: The lack of peripheral vasoconstriction seen after acute administration of celiprolol is most likely due to its partial beta-2-receptor agonistic effect and does not seem to be due to a central or reflex action or to an alpha-blocking effect. Both beta-blockers do not impair fundamental neural mechanisms involved in circulatory homeostasis.

show abstract

Section: Introductionmentioning

confidence: 99%

Cardiovascular Effects of Beta-Blockers with and without Intrinsic Sympathomimetic Activity

Heusser

Schobel²,

Adamidis³

et al. 2002

Kidney Blood Press Res

View full text Add to dashboard Cite

show abstract

Clinical pharmacology of carvedilol

et al. 1992

View full text Add to dashboard Cite

Untitled

Jost

Hausmann

Lippolt

et al. 1997

Cardiovascular Drugs and Therapy

View full text Add to dashboard Cite

Unselective and beta 1-selective beta-blockers may induce vasoconstriction of normal and stenotic epicardial coronary arteries. To analyze the influence of the "vasodilatory" beta-blocker celiprolol on coronary vasomotility, 0.4 mg celiprolol/kg were intravenously infused over 4 minutes in 13 patients with coronary artery disease. Coronary angiograms were taken before (control) and at 4, 6, 8, 10, 15, and 20 minutes after the onset of infusion and 4 minutes after final sublingual administration of 0.4 mg nitroglycerin. Quantitative analysis of cinefilms demonstrated no significant diameter changes in angiographically normal coronary segments and stenoses. The vasodilatory capacity of normal segments (18 +/- 12%; p < 0.001) and stenoses (17 +/- 14%; p < 0.01) was proven by nitroglycerin. Systolic blood pressure, heart rate, and pulmonary wedge pressure revealed no significant changes with celiprolol. Thus, celiprolol exerts no vasoconstricting effects on angiographically normal and stenotic coronary arteries.

show abstract

Haemodynamic Effects of New β-Blockers with Vasodilatory Properties in Essential Hypertension

Cited by 7 publications

References 10 publications

Cardiovascular Effects of Beta-Blockers with and without Intrinsic Sympathomimetic Activity

Cardiovascular Effects of Beta-Blockers with and without Intrinsic Sympathomimetic Activity

Clinical pharmacology of carvedilol

Untitled

Contact Info

Product

Resources

About